Nanobac Pharmaceuticals, Incorporated (NNBP)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2007 | 7.21 Million USD | -7.73% |
| 2006 | 7.82 Million USD | -12.77% |
| 2005 | 8.96 Million USD | -7.38% |
| 2004 | 9.68 Million USD | 17.47% |
| 2003 | 8.24 Million USD | 157742.04% |
| 2002 | 5223.00 USD | 0.0% |
| 1999 | 5.5 Million USD | -17.2% |
| 1998 | 6.65 Million USD | -17.94% |
| 1997 | 8.1 Million USD | -11.86% |
| 1996 | 9.19 Million USD | 31.42% |
| 1995 | 7 Million USD | 18.64% |
| 1994 | 5.9 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2007 FY | 7.21 Million USD | -7.73% |
| 2007 Q1 | 7.62 Million USD | -2.51% |
| 2007 Q3 | 7.34 Million USD | -2.73% |
| 2007 Q2 | 7.54 Million USD | -1.05% |
| 2007 Q4 | 7.21 Million USD | -1.67% |
| 2006 Q4 | 7.82 Million USD | -3.38% |
| 2006 FY | 7.82 Million USD | -12.77% |
| 2006 Q1 | 8.79 Million USD | -1.96% |
| 2006 Q3 | 8.09 Million USD | -1.56% |
| 2006 Q2 | 8.22 Million USD | -6.45% |
| 2005 Q1 | 9.54 Million USD | -1.43% |
| 2005 FY | 8.96 Million USD | -7.38% |
| 2005 Q4 | 8.96 Million USD | -1.81% |
| 2005 Q3 | 9.13 Million USD | -1.93% |
| 2005 Q2 | 9.31 Million USD | -2.42% |
| 2004 Q1 | 11.69 Million USD | 41.85% |
| 2004 Q3 | 11.17 Million USD | -2.21% |
| 2004 Q4 | 9.68 Million USD | -13.35% |
| 2004 FY | 9.68 Million USD | 17.47% |
| 2004 Q2 | 11.42 Million USD | -2.27% |
| 2003 Q3 | 10.25 Million USD | 68.73% |
| 2003 FY | 8.24 Million USD | 157742.04% |
| 2003 Q1 | 10.1 Thousand USD | 0.0% |
| 2003 Q2 | 6.07 Million USD | 60061.67% |
| 2003 Q4 | 8.24 Million USD | -19.59% |
| 2002 FY | 5223.00 USD | 0.0% |
| 2000 Q2 | 4.68 Million USD | -12.15% |
| 2000 Q1 | 5.33 Million USD | -3.15% |
| 1999 FY | 5.5 Million USD | -17.2% |
| 1999 Q3 | 6.03 Million USD | 0.0% |
| 1999 Q4 | 5.5 Million USD | -8.67% |
| 1998 FY | 6.65 Million USD | -17.94% |
| 1997 Q1 | 9.4 Million USD | 2.18% |
| 1997 FY | 8.1 Million USD | -11.86% |
| 1996 Q1 | 7.3 Million USD | 4.29% |
| 1996 FY | 9.19 Million USD | 31.42% |
| 1996 Q3 | 9.6 Million USD | 17.07% |
| 1996 Q2 | 8.2 Million USD | 12.33% |
| 1996 Q4 | 9.19 Million USD | -4.17% |
| 1995 Q2 | 5.4 Million USD | -6.9% |
| 1995 FY | 7 Million USD | 18.64% |
| 1995 Q1 | 5.8 Million USD | -1.69% |
| 1995 Q3 | 5.8 Million USD | 7.41% |
| 1995 Q4 | 7 Million USD | 20.69% |
| 1994 FY | 5.9 Million USD | 0.0% |
| 1994 Q3 | 5.9 Million USD | 0.0% |
| 1994 Q4 | 5.9 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -312443.81% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -268.696% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 31.592% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -1207.644% |
| Rebus Holdings, Inc. | 5000.00 USD | -144295.24% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 94.455% |
| Qrons Inc. | 420.00 USD | -1718890.952% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -836.848% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 74.163% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -1402.374% |
| Skye Bioscience, Inc. | 11.94 Million USD | 39.535% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 81.415% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -9355.643% |
| SQZ Biotechnologies Company | 107.18 Million USD | 93.264% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -404.162% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -9876.87% |
| Mesoblast Limited | 667.9 Million USD | 98.919% |
| Marizyme, Inc. | 22.01 Million USD | 67.205% |
| Genus plc | 1.02 Billion USD | 99.298% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -431.509% |
| Pharming Group N.V. | 462.85 Million USD | 98.44% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -117.921% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -1346.733% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -1051.477% |
| ContraFect Corporation | 20.67 Million USD | 65.087% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -1749.485% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -1789.115% |
| IMV Inc. | 31.33 Million USD | 76.959% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -74.137% |
| MultiCell Technologies, Inc. | 126.22 USD | -5719882.57% |
| ONE Bio Corp. | 70.08 Million USD | 89.699% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -668.314% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 94.382% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -1572.348% |
| Q BioMed Inc. | 3.51 Million USD | -105.368% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 79.477% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -2663.26% |
| Biomind Labs Inc. | 73.81 Thousand USD | -9680.357% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 98.382% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -398.312% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 75.946% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -162.887% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -950.169% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -177.342% |
| GB Sciences, Inc. | 103.44 Thousand USD | -6879.527% |
| Alpha Cognition Inc. | 2.45 Million USD | -194.423% |
| HST Global, Inc. | 1526.00 USD | -473016.776% |
| CSL Limited | 38.02 Billion USD | 99.981% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -630.77% |
| Halberd Corporation | 10.13 Thousand USD | -71164.061% |
| Enzolytics Inc. | 361.7 Million USD | 98.004% |
| Agentix Corp. | 261.39 Thousand USD | -2662.044% |
| Resverlogix Corp. | 8.11 Million USD | 11.032% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -284.463% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.841% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 84.865% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -1028.694% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -31592.033% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 19.325% |
| AVAX Technologies, Inc. | 7.37 Million USD | 2.134% |
| Zenith Capital Corp. | 7410.00 USD | -97332.686% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.787% |
| Ember Therapeutics, Inc. | 184.00 USD | -3923683.696% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -2143.514% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -2662.34% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -678.024% |
| Kadimastem Ltd | 2.3 Million USD | -213.347% |
| Helix BioMedix, Inc. | 3.02 Million USD | -138.663% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 86.301% |
| BioStem Technologies, Inc. | 14.56 Million USD | 50.415% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -12545.395% |
| LadRx Corporation | 2.3 Million USD | -212.831% |
| Cell Source, Inc. | 195.17 Thousand USD | -3599.198% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -1941.69% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -1941.69% |
| NovAccess Global Inc. | 62.24 Thousand USD | -11498.384% |
| Affymax, Inc. | 7.44 Million USD | 2.999% |
| Itoco Inc. | 1.4 Million USD | -415.671% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -7447.552% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -6711.096% |
| Mobile Lads Corp. | 52.00 USD | -13884057.692% |
| CytoDyn Inc. | 11.13 Million USD | 35.167% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -4949.773% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -40278.982% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -1772.972% |
| SYBLEU INC | 330.46 Thousand USD | -2084.708% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -1663.404% |
| International Stem Cell Corporation | 5.39 Million USD | -33.947% |
| Bioxytran, Inc. | 137.63 Thousand USD | -5145.471% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 51.874% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 56.452% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -9038.939% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -734.966% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 3.954% |
| Neutra Corp. | 2851.00 USD | -253136.128% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 77.721% |
| PureTech Health plc | 693.97 Million USD | 98.96% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 10.548% |
| IXICO plc | 15.84 Million USD | 54.432% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 12.826% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 93.013% |
| CSL Limited | 38.02 Billion USD | 99.981% |
| Cellectis S.A. | 333.99 Million USD | 97.838% |